NEW YORK (GenomeWeb) – Fluxion Biosciences announced today that it has signed a distribution agreement for its BioFlux and IonFlux cellular analysis platforms with Harvard Bioscience.
BioFlux enables automated, high-throughput studies of cell-cell interactions, while microfluidics-based IonFlux is designed for ion channel research and drug discovery. Under the terms of the deal, Harvard Bioscience will offer the platforms to its customers in North America. Additional terms were not disclosed.
"IonFlux is a perfect fit with our other electrophysiology products, and extends our capabilities to high-throughput automated analysis," John Battista, North American sales director for electrophysiology products at Harvard Bioscience, said in a statement. "Similarly, the BioFlux system is a natural extension of our well-established Warner Instruments flow cell portfolio, permitting higher-throughput, microfluidic processing of eukaryotic and bacterial assays under flow."